Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium

@inproceedings{Seferina2017CostAC,
  title={Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium},
  author={Shanly C. Seferina and Bram L T Ramaekers and Maaike de Boer and Marcus Wouter Dercksen and Franchette W P J van den Berkmortel and Roel J.W. van Kampen and Agn{\`e}s J. van de Wouw and A C Voogd and Vivianne C.G. Tjan Heijnen and Manuela M A Joore},
  booktitle={Oncotarget},
  year={2017}
}
Background We assessed the real world costs and cost-effectiveness of the addition of trastuzumab in HER2 positive early breast cancer compared to chemotherapy alone in the Dutch daily practice as opposed to the results based on trial data and based on a subset of patients that were treated according to the guidelines. Patients and Methods In a cohort… CONTINUE READING